Evercore ISI resumed coverage of Bausch + Lomb with an Outperform rating and $20 price target after the firm had previously suspended coverage.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BLCO:
- Novartis completes divestment of ‘front of eye’ ophthalmology assets
- Bausch + Lomb completes acquisition of Xiidra from Novartis
- Needham medtech/diagnostics analysts hold analyst/industry conference call
- Bausch + Lomb launches LUMIFY EYE ILLUMINATIONS in U.S.
- Bausch Health upgraded to Buy from Hold at Jefferies